

Systemic Sclerosis

**A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) (FocuSSced)**

**Trial Status**  
Completed

**Trial Runs In**  
22 Countries

**Trial Identifier**  
NCT02453256 2015-000424-28  
WA29767

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study will assess the efficacy and safety of tocilizumab compared with placebo in participants with SSc across approximately 120 planned global study sites. The study will consist of a 48-week, double-blind, placebo-controlled period followed by a 48-week open-label treatment period. Participants will be assigned, in a 1:1 ratio, to double-blind treatment with active tocilizumab or matching placebo. In the open-label period, eligible participants from either arm may receive active tocilizumab.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

**NCT02453256 2015-000424-28 WA29767**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No